The Duchenne Lottery: Why Where a Child Lives May Now Matter More Than Ever

By Helena Marsh

There is an uncomfortable truth emerging in the world of Duchenne muscular dystrophy, and families everywhere are beginning to say it out loud.

For decades, the cruelest aspect of Duchenne was biology itself — a genetic mutation silently robbing children of muscle strength, mobility, independence, and eventually critical heart and lung function. Parents learned to fear birthdays not because of aging, but because every passing year often brought irreversible loss.

But in 2026, another painful reality has joined the fight.

For many families, the future of a child with Duchenne may now depend not only on science or medicine, but on geography.

A child living in Boston may have access to options that remain unavailable to families in Berlin. A boy in Tokyo may receive treatment that remains inaccessible to families in São Paulo, Toronto, or Tbilisi. Increasingly, parents in the Duchenne community are confronting a disturbing question: Has Duchenne become a global lottery?

At the center of this debate is ELEVIDYS, the world’s first approved gene therapy for Duchenne muscular dystrophy, developed by Sarepta Therapeutics. The treatment is designed to introduce a shortened but functional version of dystrophin — the protein missing in Duchenne patients — through a viral delivery system. It does not cure Duchenne, but it represents something families had waited decades to see: an attempt to address the disease at its genetic root rather than simply slowing decline.

In 2024, the U.S. Food and Drug Administration expanded approval of ELEVIDYS for patients aged four years and older with a confirmed Duchenne mutation, including both ambulatory and non-ambulatory individuals. At the same time, evidence of long-term clinical benefit continues to be evaluated through ongoing confirmatory studies, reflecting both the promise and complexity of this new therapeutic era.

Then came the divide.

While the United States moved ahead, European regulators moved in the opposite direction.

In July 2025, the European Medicines Agency recommended against granting marketing authorization for ELEVIDYS, arguing that the available evidence had not sufficiently demonstrated meaningful long-term clinical benefit. Roche, which holds commercialization rights outside the United States, returned to the clinical trial arena, launching another major study in 2026 in hopes of eventually securing European approval.

The consequences of that regulatory disagreement are impossible to ignore.

For families, this is not merely a scientific debate over statistical significance or endpoints buried in clinical trial spreadsheets. Every month matters in Duchenne. A child who loses the ability to climb stairs this year may never regain it. Muscle degeneration does not pause while regulators deliberate.

This has created a deeply emotional fault line inside the global Duchenne community.

Many parents outside the United States increasingly watch American families access therapies they cannot obtain at home. Online support groups have become filled with difficult questions: Should families relocate? Fundraise internationally? Seek treatment abroad? Wait for local approvals? Or accept that bureaucracy may move slower than the disease itself?

At the same time, the story is more complicated than many headlines suggest.

Even in the United States, ELEVIDYS has not escaped controversy. Safety concerns, including serious adverse events and questions about the durability of benefit, have prompted intense scrutiny. In 2025, treatment administration faced temporary interruptions and heightened regulatory review following reports of serious adverse events in specific patient populations. Supporters argue that waiting for perfect evidence condemns children to irreversible decline. Critics warn that approving extraordinarily expensive therapies before long-term outcomes are fully understood risks exposing vulnerable patients to uncertain benefits and significant risks.

Yet while regulators debate, another reality quietly unfolds: science keeps moving.

Japan commercially launched ELEVIDYS in 2026 for eligible children with Duchenne, joining a growing number of countries willing to expand access while additional evidence continues to accumulate. Meanwhile, Sarepta has reported expanding real-world evidence from more than 1,200 treated patients and continues pursuing additional regulatory approvals and next-generation Duchenne programs.

To parents, however, the central issue remains painfully simple.

No mother or father raising a child with Duchenne experiences the disease in quarterly milestones or regulatory terminology. They experience it in lost steps. In missed playground moments. In wheelchairs that arrive earlier than expected. In subtle changes visible only to parents who notice every movement their child can no longer make.

And perhaps that is what makes the current moment in Duchenne so emotionally charged.

For the first time in history, some families can realistically believe that science may alter the course of this disease. Yet for countless families around the world, that possibility remains shaped by healthcare systems, reimbursement structures, regulatory decisions, and broader public policy choices.

The scientific revolution families prayed for may finally be arriving.

The tragedy many fear is that it may not arrive equally.

Editorial Note: This article reflects the perspectives and concerns increasingly voiced within the global Duchenne community and is not intended as medical advice. Treatment decisions should always be made in consultation with qualified healthcare professionals and according to local regulatory guidance.

Sources

• U.S. Food and Drug Administration: ELEVIDYS approval expansion (2024).
• European Medicines Agency opinion regarding ELEVIDYS (2025).
• Roche announcements regarding follow-up clinical studies in Europe (2026).
• Reporting on safety-related regulatory reviews and treatment interruptions: Reuters, Fierce Pharma, BioPharma Dive, and STAT.
• Sarepta Therapeutics updates regarding Japan launch and real-world evidence.